Literature DB >> 36262497

Evidence-based Role of Aspirin in Giant Cell Arteritis: A Literature Review.

Anum Qureshi1, Fatima Halilu1, Sam W Serafi1,2, Howard Hauptman1,2, Tristan Flack1.   

Abstract

Giant cell arteritis (GCA), or temporal arteritis, is a medium to large vessel vasculitis seen in the elderly. Its presentation varies from fever of unknown origin to cranial ischemic complications including complete vision loss. The early initiation of steroids is key to preventing complications of GCA. Here we discuss the role of aspirin in the treatment of GCA, both as an antithrombotic agent and its increasingly utilized anti-inflammatory properties. The aim of this review article is to examine the evidence behind the use of aspirin as an adjunct to steroids for the prevention of cranial ischemic complications.
© 2022 Greater Baltimore Medical Center.

Entities:  

Keywords:  Anticoagulants; Antiplatelets; Aspirin; Giant cell arteritis; Prednisone

Year:  2022        PMID: 36262497      PMCID: PMC9529650          DOI: 10.55729/2000-9666.1072

Source DB:  PubMed          Journal:  J Community Hosp Intern Med Perspect        ISSN: 2000-9666


  30 in total

Review 1.  Polymyalgia rheumatica and giant cell arteritis.

Authors:  Brian Unwin; Cynthia M Williams; William Gilliland
Journal:  Am Fam Physician       Date:  2006-11-01       Impact factor: 3.292

2.  Therapy for giant cell arteritis: can we do better?

Authors:  Robert F Spiera; Harry Spiera
Journal:  Arthritis Rheum       Date:  2006-10

Review 3.  The treatment of giant cell arteritis.

Authors:  J Alexander Fraser; Cornelia M Weyand; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

4.  Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis.

Authors:  M Kaiser; C M Weyand; J Björnsson; J J Goronzy
Journal:  Arthritis Rheum       Date:  1998-04

5.  The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee.

Authors:  C A Smith; W J Fidler; R S Pinals
Journal:  Arthritis Rheum       Date:  1983-10

6.  High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.

Authors:  C T Berger; M Wolbers; P Meyer; T Daikeler; C Hess
Journal:  Rheumatology (Oxford)       Date:  2009-01-07       Impact factor: 7.580

7.  Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin.

Authors:  H Tohgi; S Konno; K Tamura; B Kimura; K Kawano
Journal:  Stroke       Date:  1992-10       Impact factor: 7.914

8.  Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies.

Authors:  Sohan Singh Hayreh; Bridget Zimmerman
Journal:  Ophthalmologica       Date:  2003 Jul-Aug       Impact factor: 3.250

9.  Trial of Tocilizumab in Giant-Cell Arteritis.

Authors:  John H Stone; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Martin Aringer; Daniel Blockmans; Elisabeth Brouwer; Maria C Cid; Bhaskar Dasgupta; Juergen Rech; Carlo Salvarani; Georg Schett; Hendrik Schulze-Koops; Robert Spiera; Sebastian H Unizony; Neil Collinson
Journal:  N Engl J Med       Date:  2017-07-27       Impact factor: 91.245

10.  Giant cell arteritis: a multicenter observational study in Brazil.

Authors:  Alexandre Wagner Silva de Souza; Karine Yoshiye Kajiyama Okamoto; Fabiano Abrantes; Bruno Schau; Ana Beatriz Santos Bacchiega; Samuel Katsuyuki Shinjo
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.